Kimberly G Blumenthal1, Robert A Parker2, Erica S Shenoy3, Rochelle P Walensky4. 1. Division of Rheumatology, Allergy, and Immunology, Department of Medicine Medical Practice Evaluation Center, Massachusetts General Hospital Harvard Medical School. 2. Medical Practice Evaluation Center, Massachusetts General Hospital Harvard Medical School Biostatistics Center, Department of Medicine, Massachusetts General Hospital, Boston. 3. Medical Practice Evaluation Center, Massachusetts General Hospital Harvard Medical School Infection Control Unit Division of Infectious Disease, Department of Medicine. 4. Medical Practice Evaluation Center, Massachusetts General Hospital Harvard Medical School Division of Infectious Disease, Department of Medicine.
Abstract
BACKGROUND: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a morbid infection. First-line MSSA therapies (nafcillin, oxacillin, cefazolin) are generally avoided in the 10% of patients reporting penicillin (PCN) allergy, but most of these patients are not truly allergic. We used a decision tree with sensitivity analyses to determine the optimal evaluation and treatment for patients with MSSA bacteremia and reported PCN allergy. METHODS: Our model simulates 3 strategies: (1) no allergy evaluation, give vancomycin (Vanc); (2) allergy history-guided treatment: if history excludes anaphylactic features, give cefazolin (Hx-Cefaz); and (3) complete allergy evaluation with history-appropriate PCN skin testing: if skin test negative, give cefazolin (ST-Cefaz). Model outcomes included 12-week MSSA cure, recurrence, and death; allergic reactions including major, minor, and potentially iatrogenic; and adverse drug reactions. RESULTS: Vanc results in the fewest patients achieving MSSA cure and the highest rate of recurrence (67.3%/14.8% vs 83.4%/9.3% for Hx-Cefaz and 84.5%/8.9% for ST-Cefaz) as well as the greatest frequency of allergic reactions (3.0% vs 2.4% for Hx-Cefaz and 1.7% for ST-Cefaz) and highest rates of adverse drug reactions (5.2% vs 4.6% for Hx-Cefaz and 4.7% for ST-Cefaz). Even in a "best case for Vanc" scenario, Vanc yields the poorest outcomes. ST-Cefaz is preferred to Hx-Cefaz although sensitive to input variations. CONCLUSIONS: Patients with MSSA bacteremia and a reported PCN allergy should have the allergy addressed for optimal treatment. Full allergy evaluation with skin testing seems to be preferred, although more data are needed.
BACKGROUND: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a morbid infection. First-line MSSA therapies (nafcillin, oxacillin, cefazolin) are generally avoided in the 10% of patients reporting penicillin (PCN) allergy, but most of these patients are not truly allergic. We used a decision tree with sensitivity analyses to determine the optimal evaluation and treatment for patients with MSSA bacteremia and reported PCN allergy. METHODS: Our model simulates 3 strategies: (1) no allergy evaluation, give vancomycin (Vanc); (2) allergy history-guided treatment: if history excludes anaphylactic features, give cefazolin (Hx-Cefaz); and (3) complete allergy evaluation with history-appropriate PCN skin testing: if skin test negative, give cefazolin (ST-Cefaz). Model outcomes included 12-week MSSA cure, recurrence, and death; allergic reactions including major, minor, and potentially iatrogenic; and adverse drug reactions. RESULTS:Vanc results in the fewest patients achieving MSSA cure and the highest rate of recurrence (67.3%/14.8% vs 83.4%/9.3% for Hx-Cefaz and 84.5%/8.9% for ST-Cefaz) as well as the greatest frequency of allergic reactions (3.0% vs 2.4% for Hx-Cefaz and 1.7% for ST-Cefaz) and highest rates of adverse drug reactions (5.2% vs 4.6% for Hx-Cefaz and 4.7% for ST-Cefaz). Even in a "best case for Vanc" scenario, Vanc yields the poorest outcomes. ST-Cefaz is preferred to Hx-Cefaz although sensitive to input variations. CONCLUSIONS:Patients with MSSA bacteremia and a reported PCN allergy should have the allergy addressed for optimal treatment. Full allergy evaluation with skin testing seems to be preferred, although more data are needed.
Authors: Matthieu Picard; Philippe Bégin; Hugues Bouchard; Jonathan Cloutier; Jonathan Lacombe-Barrios; Jean Paradis; Anne Des Roches; Brian Laufer; Louis Paradis Journal: J Allergy Clin Immunol Pract Date: 2013-02-14
Authors: V G Fowler; L K Kong; G R Corey; G S Gottlieb; R S McClelland; D J Sexton; D Gesty-Palmer; L J Harrell Journal: J Infect Dis Date: 1999-05 Impact factor: 5.226
Authors: M Blanca; M J Torres; J J García; A Romano; C Mayorga; E de Ramon; J M Vega; A Miranda; C Juarez Journal: J Allergy Clin Immunol Date: 1999-05 Impact factor: 10.793
Authors: Kevin E Chan; H Shaw Warren; Ravi I Thadhani; David J R Steele; Jeffrey L Hymes; Franklin W Maddux; Raymond M Hakim Journal: J Am Soc Nephrol Date: 2012-08-16 Impact factor: 10.121
Authors: Ramzy H Rimawi; Paul P Cook; Michael Gooch; Badih Kabchi; Muhammad S Ashraf; Bassam H Rimawi; Mulugeta Gebregziabher; Dawd S Siraj Journal: J Hosp Med Date: 2013-04-03 Impact factor: 2.960
Authors: Anca M Chiriac; Aleena Banerji; Rebecca S Gruchalla; Bernard Y H Thong; Paige Wickner; Paul-Michel Mertes; Ingrid Terreehorst; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2018-12-17
Authors: Thomas L Holland; Larry M Baddour; Arnold S Bayer; Bruno Hoen; Jose M Miro; Vance G Fowler Journal: Nat Rev Dis Primers Date: 2016-09-01 Impact factor: 52.329
Authors: Kimberly G Blumenthal; Nicolas M Oreskovic; Xiaoqing Fu; Fatma M Shebl; Christian M Mancini; Jennifer M Maniates; Rochelle P Walensky Journal: Am J Manag Care Date: 2020-04 Impact factor: 2.229
Authors: Jason A Trubiano; Cosby A Stone; M Lindsay Grayson; Karen Urbancic; Monica A Slavin; Karin A Thursky; Elizabeth J Phillips Journal: J Allergy Clin Immunol Pract Date: 2017-08-23
Authors: Kimberly G Blumenthal; Erica S Shenoy; Anna R Wolfson; David N Berkowitz; Victoria A Carballo; Diana S Balekian; Kathleen A Marquis; Ramy Elshaboury; Ronak G Gandhi; Praveen Meka; David W Kubiak; Jennifer Catella; Barbara B Lambl; Joyce T Hsu; Monique M Freeley; Alana Gruszecki; Paige G Wickner Journal: J Allergy Clin Immunol Pract Date: 2017 May - Jun
Authors: Cosby A Stone; Jason Trubiano; David T Coleman; Christine R F Rukasin; Elizabeth J Phillips Journal: Allergy Date: 2019-05-26 Impact factor: 13.146